Literature DB >> 3324443

Transferrin receptor expression by human bladder transitional cell carcinomas.

G J Seymour1, M D Walsh, M F Lavin, G Strutton, R A Gardiner.   

Abstract

The expression of transferrin receptors (TFR) by normal and neoplastic urothelial cells was studied in "control" patients and in patients with transitional cell carcinoma of the bladder. These tumours were graded independently and consisted of 19 grade I, 30 grade II and 19 grade III lesions. TFRs were identified using a monoclonal antibody specific for TFR (OKT9) in an immunofluorescent or avidin/biotin-immunoperoxidase technique on fresh frozen sections. TFRs were not detected on normal urothelium. However, positive staining was found to increase with increasing pathological grade and stage of the tumours, ranging from 31.6% of grade I to 78.9% of grade III tumours and 51.2% of pTa (mucosa only lesions) to 87.5% of pT2/pT2+ (muscle invasion +/- deeper) primary urothelial malignancies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3324443     DOI: 10.1007/bf00265663

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  16 in total

Review 1.  Applications of monoclonal antibodies in cancer therapy.

Authors:  R O Dillman; I Royston
Journal:  Br Med Bull       Date:  1984-07       Impact factor: 4.291

2.  Growth stimulating activity produced by human bladder cancer cells.

Authors:  E M Messing; J E Bubbers; J B Dekernion; J L Fahey
Journal:  J Urol       Date:  1984-12       Impact factor: 7.450

Review 3.  Cancer, oncogenes and oncofetal antigens.

Authors:  M Adinolfi; M H Lessof
Journal:  Q J Med       Date:  1985-03

4.  Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro.

Authors:  I S Trowbridge; F Lopez
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

5.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

6.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

7.  Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin.

Authors:  R Sutherland; D Delia; C Schneider; R Newman; J Kemshead; M Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

8.  Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells.

Authors:  R Taetle; J M Honeysett; I Trowbridge
Journal:  Int J Cancer       Date:  1983-09-15       Impact factor: 7.396

9.  Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions.

Authors:  I Tannock; P Guttman
Journal:  Br J Cancer       Date:  1981-02       Impact factor: 7.640

10.  ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma.

Authors:  M V Viola; F Fromowitz; S Oravez; S Deb; J Schlom
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

2.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

3.  Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

Authors:  Jolyn Turner; Constantinos Koumenis; Timothy E Kute; Roy P Planalp; Martin W Brechbiel; Dillon Beardsley; Brooke Cody; Kevin D Brown; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

4.  Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction.

Authors:  R Prior; G Reifenberger; W Wechsler
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 5.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 6.  A ubiquitous metal, difficult to track: towards an understanding of the regulation of titanium(iv) in humans.

Authors:  Sergio A Loza-Rosas; Manoj Saxena; Yamixa Delgado; Kavita Gaur; Mallesh Pandrala; Arthur D Tinoco
Journal:  Metallomics       Date:  2017-04-19       Impact factor: 4.526

Review 7.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

8.  Flow cytometric evaluation of Thomsen-Friedenreich antigen on transitional cell cancer using monoclonal antibody.

Authors:  H Oda; T Oda; H Ohoka; M Yokoyama; M Takeuchi
Journal:  Urol Res       Date:  1990

9.  A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells.

Authors:  Megumi Kawamoto; Tomohisa Horibe; Masayuki Kohno; Koji Kawakami
Journal:  BMC Cancer       Date:  2011-08-18       Impact factor: 4.430

10.  Binding of RuCp complexes with human apo-transferrin: fluorescence spectroscopy and molecular docking methods.

Authors:  Filipa C Santos; Paulo J Costa; M Helena Garcia; Tânia S Morais
Journal:  Biometals       Date:  2021-06-22       Impact factor: 2.949

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.